De-escalating and discontinuing disease-modifying therapies in multiple sclerosis - Takeaways - MDSpire

De-escalating and discontinuing disease-modifying therapies in multiple sclerosis

  • By

  • Géraldine Androdias

  • Jan D Lünemann

  • Elisabeth Maillart

  • Maria Pia Amato

  • Bertrand Audoin

  • Arlette L Bruijstens

  • Gabriel Bsteh

  • Helmut Butzkueven

  • Olga Ciccarelli

  • Alvaro Cobo-Calvo

  • Tobias Derfuss

  • Franziska Di Pauli

  • Gilles Edan

  • Christian Enzinger

  • Ruth Geraldes

  • Cristina Granziera

  • Yael Hacohen

  • Hans-Peter Hartung

  • Sinéad Hynes

  • Matilde Inglese

  • Ludwig Kappos

  • Hanna Kuusisto

  • Annette Langer-Gould

  • Melinda Magyari

  • Romain Marignier

  • Xavier Montalban

  • Marcin P Mycko

  • Bardia Nourbakhsh

  • Jiwon Oh

  • Celia Oreja-Guevara

  • Fredrik Piehl

  • Luca Prosperini

  • Jaume Sastre-Garriga

  • Finn Sellebjerg

  • Krzysztof Selmaj

  • Aksel Siva

  • Emma Tallantyre

  • Vincent van Pesch

  • Sandra Vukusic

  • Bianca Weinstock-Guttman

  • Frauke Zipp

  • Mar Tintoré

  • Ellen Iacobaeus

  • Bruno Stankoff

  • December 21, 2024

  • 0 min

Share

  • 1

    Disease-modifying therapies (DMTs) for multiple sclerosis (MS) have evolved significantly, improving long-term patient outcomes.

  • 2

    Early initiation of DMTs after MS onset is linked to better prognosis, emphasizing the importance of timely treatment.

  • 3

    De-escalation strategies for DMTs are necessary to reassess treatment plans based on changing benefit-risk ratios.

  • 4

    The 2023 ECTRIMS workshop aimed to establish evidence-based guidelines for de-escalating and discontinuing DMTs in MS.

  • 5

    Immunosenescence and inflammaging significantly impact treatment effectiveness and risks in older MS patients.

Original Source(s)

De-escalating and discontinuing disease-modifying therapies in multiple sclerosis

  • by Géraldine Androdias, Jan D Lünemann, Elisabeth Maillart, Maria Pia Amato, Bertrand Audoin, Arlette L Bruijstens, Gabriel Bsteh, Helmut Butzkueven, Olga Ciccarelli, Alvaro Cobo-Calvo, Tobias Derfuss, Franziska Di Pauli, Gilles Edan, Christian Enzinger, Ruth Geraldes, Cristina Granziera, Yael Hacohen, Hans-Peter Hartung, Sinéad Hynes, Matilde Inglese, Ludwig Kappos, Hanna Kuusisto, Annette Langer-Gould, Melinda Magyari, Romain Marignier, Xavier Montalban, Marcin P Mycko, Bardia Nourbakhsh, Jiwon Oh, Celia Oreja-Guevara, Fredrik Piehl, Luca Prosperini, Jaume Sastre-Garriga, Finn Sellebjerg, Krzysztof Selmaj, Aksel Siva, Emma Tallantyre, Vincent van Pesch, Sandra Vukusic, Bianca Weinstock-Guttman, Frauke Zipp, Mar Tintoré, Ellen Iacobaeus, Bruno Stankoff

  • December 21, 2024

Related Content

Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights

Hippocampal neuronal hypoexcitability contributes to PTSD-like phenotypes in the experimental autoimmune encephalomyelitis model

Digging deeper into NINJ1: its multifaceted role in central nervous system diseases